Prevalence of medical ghost-writing still a concern, warns Senator Grassley
This article was originally published in Scrip
Efforts by medical journals in recent years to strengthen their authorship and publication requirements appear to have had limited effect on ghost-writing and disclosure of industry financing of medical articles, says a new report released by US Senator Chuck Grassley (Republican – Iowa).
You may also be interested in...
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
The Australian health care products regulator is inviting feedback on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices.
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.